Ocugen's OCU410 Gets FDA Nod for Phase 3, RMAT Designation; Cash Runway Extended to 2028
OCGN sits 39% above its 52-week low of $0.931.
Summary
Ocugen's Q2 update delivers multiple clinical catalysts: FDA clearance to start the OCU410 Phase 3 trial in geographic atrophy, plus RMAT designation enabling priority review and accelerated approval. The pivotal OCU410ST trial in Stargardt disease completed enrollment ahead of schedule, with topline data now expected in Q2 2027. OCU400 PPQ batches are done, clearing a manufacturing hurdle for the BLA submission after Q1 2027 RP data. The $130M convertible note closed in May extends cash runway into 2028, de-risking the path to these readouts. This follows the OCU400 MENA licensing deal and the proxy seeking share authorization for note conversion — the pipeline is advancing on multiple fronts. Key watchpoints: OCU400 topline results in Q1 2027 and OCU410ST data in Q2 2027.
At the time of this announcement, OCGN was trading at $1.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $434.1M. The 52-week trading range was $0.93 to $2.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.